Literature DB >> 20435838

To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?

Carl J Lavie1, Richard V Milani, James H O'Keefe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20435838      PMCID： PMC2861974          DOI： 10.4065/mcp.2010.0058

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  35 in total

Review 1.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.

Authors:  James H O'Keefe; Loren Cordain; William H Harris; Richard M Moe; Robert Vogel
Journal:  J Am Coll Cardiol       Date:  2004-06-02       Impact factor: 24.094

2.  Are you targeting non-high-density lipoprotein cholesterol?

Authors:  Jennifer G Robinson
Journal:  J Am Coll Cardiol       Date:  2009-12-29       Impact factor: 24.094

3.  Statin wars: emphasis on potency vs event reduction and safety?

Authors:  Carl J Lavie; Richard V Milani; James H O'Keefe
Journal:  Mayo Clin Proc       Date:  2007-05       Impact factor: 7.616

Review 4.  Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.

Authors:  John D Brunzell; Michael Davidson; Curt D Furberg; Ronald B Goldberg; Barbara V Howard; James H Stein; Joseph L Witztum
Journal:  Diabetes Care       Date:  2008-04       Impact factor: 19.112

5.  Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.

Authors:  Benoit J Arsenault; Jamal S Rana; Erik S G Stroes; Jean-Pierre Després; Prediman K Shah; John J P Kastelein; Nicholas J Wareham; S Matthijs Boekholdt; Kay-Tee Khaw
Journal:  J Am Coll Cardiol       Date:  2009-12-29       Impact factor: 24.094

Review 6.  C-reactive protein and cardiovascular diseases--is it ready for primetime?

Authors:  Carl J Lavie; Richard V Milani; Anil Verma; James H O'Keefe
Journal:  Am J Med Sci       Date:  2009-12       Impact factor: 2.378

7.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

Review 8.  Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach.

Authors:  James H O'Keefe; Maia D Carter; Carl J Lavie
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

Review 9.  The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.

Authors:  Gustavo A Cardenas; Carl J Lavie; Vanessa Cardenas; Richard V Milani; Peter A McCullough
Journal:  Rev Cardiovasc Med       Date:  2008       Impact factor: 2.930

Review 10.  Omega-3 fatty acids for cardioprotection.

Authors:  John H Lee; James H O'Keefe; Carl J Lavie; Roberto Marchioli; William S Harris
Journal:  Mayo Clin Proc       Date:  2008-03       Impact factor: 7.616
View more
  5 in total

1.  Using apolipoprotein B to manage dyslipidemia.

Authors:  Jennifer G Robinson
Journal:  Mayo Clin Proc       Date:  2010-08       Impact factor: 7.616

Review 2.  The role of non-HDL cholesterol in risk stratification for coronary artery disease.

Authors:  Jamal S Rana; S Matthijs Boekholdt; John J P Kastelein; Prediman K Shah
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

Review 3.  Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

4.  Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia.

Authors:  O P Ganda; C G Jumes; M J Abrahamson; M Molla
Journal:  Diabetes Res Clin Pract       Date:  2012-03-28       Impact factor: 5.602

5.  Non-HDL as a Valid Surrogate Marker of Small Dense LDL in a Young Indian Population.

Authors:  Anjali Manocha; Seema Bhargava; Rajneesh Jain; Mamta Kankra; Parul Singla; Parul Chugh
Journal:  Indian J Clin Biochem       Date:  2018-05-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.